- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Carl Zeiss Meditec to acquire Acri.Tec AG
Jena, Germany-Zeiss Meditec hopes to obtain Acri.Tec AG, a leading company in implants for ophthalmic surgery.
Jena, Germany-Carl Zeiss Meditec, a medical technology provider, hopes to obtain Acri.Tec AG, a leading company in implants for ophthalmic surgery. In 2006, Acri.Tec AG's sales totaled €15.4 million in innovative implants and other products for ophthalmic surgery.
The actual purchase price will be determined once it is reduced by net financial debt at the closing date. October 2007 is when the transaction should be completed as long as the German anti-trust authority approves it and contractually agreed conditions have been met.
Ulrich Krauss, president and CEO of Carl Zeiss Meditec, in a prepared statement said Acri.Tec has a name as well recognized as Zeiss and is an important step in the expansion of its product portfolio, especially for innovative IOLs.
Besides devices for diagnosis, treatment and aftercare, the acquisition will also incorporate IOLs for cataract treatments and to correct vision defects. The transaction will also strengthen Carl Zeiss Meditec's business in Germany, according to Krauss.
